0.00Open0.10Pre Close0 Volume4 Open Interest55.00Strike Price0.00Turnover7707.70%IV29.71%PremiumNov 22, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0237Delta0.0053Gamma781.00Leverage Ratio-210.7122Theta0.0000Rho-18.55Eff Leverage0.0001Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet